This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Emgality
  • /
  • Evaluation of Galcanezumab in the Prevention of Ep...
Clinical trial

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1)

Read time: 1 mins
Last updated:16th Jun 2020
Status: Completed
Identifier: NCT02614183
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1)


The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 862 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study
Actual Study Start Date: November 30, 2015
Actual Primary Completion Date: March 22, 2017
Actual Study Completion Date: August 9, 2018

Arms:
- Experimental:
Galcanezumab 120mg
- Experimental: Galcanezumab 240mg
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Expected enrolment 862
Actual Study start date 30 November 2015
Actual Study Completion Date 09 August 2018

View full details